TVA Medical of Austin, Texas, a newly acquired subsidiary of Becton Dickinson, won de novo marketing clearance from the FDA for its innovative everlinQ endoAVF system for creating arteriovenous fistulas for hemodialysis without relying on open surgery.
The system relies on catheters inserted into adjoining arteries and veins. When in proximity, built-in magnets within the catheters attract each other and snap the catheter pair together. A small electrode is then used to ablate the tissue between the catheters, creating a fistula.
The location of the catheters and whether they have snapped together can be seen under X-ray fluoroscopy, helping to assure proper placement and delivery of RF energy.
Because dialysis patients typically have to undergo more invasive procedures, the company hopes that adoption of its technology will lead to improved patient satisfaction while reducing failure rates.
Here’s a video explaining the workings of the new system:
Product page: everlinQ endoAVF System…
Via: TVA Medical…
Via: TVA Medical…